Global ADC treatment market will increase to 4 billion US dollars in 2023

In particular, CMO (contract production business) and cdmo (contract production R & D business) should take full advantage of the growing opportunities of this therapeutic product category, and may even lead to new business models According to the latest analysis in the annual report of CPHI, the global ADC treatment market is expected to grow to 4 billion US dollars by 2023, and there are two digit new antibody drug conjugate (hereinafter referred to as ADC) drugs approved in three years The full content of its findings has been in CPHI Worldwide in real time (Madrid, Spain, 9-11 October 2018) Vivek, CEO of Piramal Pharma solutions, a specialized agency that writes CPHI's annual report Sharma) predicts that the global ADC market will grow at a compound annual rate of about 19% from 2017 to 2030 and an estimated $4 billion in the next five years, with 17 drugs, including those approved or in the later stage of clinical development, catalyzing this growth In recent years, the target of attention has gradually evolved from the first generation to the second generation and the third generation of ADC At present, the growth is accelerating, because the new ADC compounds are more targeted, more drug-resistant, and may have greater opportunities for approval The understanding of site-specific and homologous coupled ADCs has accelerated the FDA's approval rate for them, and led to a sharp increase in the number of clinical trials, especially in the field of solid tumor treatment At present, there are 600 clinical trials involving ADC in the world, of which 202 are entering the clinical trial stage - 116 are actively advancing Most encouraging is that in the past 12 months, 23 new ADCs have entered the corresponding clinical trials, an increase of 30% In particular, CMO (contract production business) and cdmo (contract production R & D business) should take full advantage of the growing opportunities of this therapeutic product category, which may even lead to new business models, such as co development with innovative companies, the report said Partnership, especially with small and medium-sized biotechnology companies The global ADC market is expected to be driven by advances in medical technology, increased incidence rate of cancer, and increasing demand for biotherapy In order to seek more targeted therapies and possibly more clinically effective drugs, biological / pharmaceutical companies are increasing their research and product development investment in biological agents Due to the technical challenges associated with ADC manufacturing and the large investment required for safety and hazardous materials and equipment, vivec estimates that about 70% of ADC manufacturing will be outsourced to CMOS It is expected that this trend will be further developed, especially for the horizontally integrated cdmo, as well as the joint development business model, which is particularly driven by biotechnology companies and small companies that need specialized development expertise and facilities The annual report also highlights that ADC is now being used in the long run by therapeutic products other than oncology Specifically, ADC is expected to provide more targeted treatment in infectious diseases (for multidrug-resistant bacteria) and chronic diseases such as autoimmune and cardiovascular diseases Orhan caglayan, European director of CPHI brand, added: "the findings in CPHI's annual full report further emphasize that there is an obvious bridge between the small molecule drugs and the large molecule drugs (including ADC) industry today, and the knowledge cross sharing in ADC market leads to the reduction of clinical costs and the approval of more new drugs So it's obviously good news for both CPHI and biolive CMO companies and cdmo companies can take advantage of this opportunity CPHI has integrated the 2018 exhibition of small molecule drugs and large molecule drugs For cdmo, the market prospect is very broad, and more extensive outsourcing will enable more than 70% of the manufacturing industry to sign contracts with professional suppliers in the future.